琥珀酸他舒格替尼用药指南

Tasugatinib succinate is a targeted therapy for patients with unresectable biliary tract cancer carrying FGFR2 gene fusions or rearrangements. The drug was developed by Japan's Eisai Co., Ltd. and was approved for marketing in Japan in September 2024. It has not yet entered the Chinese market. The recommended dose is 140 mg once a day, which needs to be taken on an empty stomach, and the dose should be adjusted according to the patient's response. Common side effects include hyperphosphatemia, retinal detachment, diarrhea, etc. Serum phosphorus concentration and eye health need to be monitored regularly.

Tasugetinib succinate medication guide

It is a targeted drug for patients with biliary tract cancer with specific genetic abnormalities, and its use must strictly follow the guidelines.

Indications and Targets

Tasugatinib succinate is suitable for patients with unresectable biliary tract cancer who have progressed after chemotherapy and carry FGFR2 gene fusion or rearrangement. Its targets are FGFR1, FGFR2 and FGFR3, blocking tumor growth signals by inhibiting the activity of these receptors.

Usage and dosage

The recommended dose for adults is 140 mg once a day, taken on an empty stomach. The dose can be gradually adjusted according to the patient's tolerance: from 140 mg to 105 mg, 70 mg or 35 mg until the drug is discontinued. The specific dose reduction needs to be determined based on the severity of adverse reactions.

Adverse reaction management

Hyperphosphatemia and retinal detachment are serious side effects that require careful monitoring. Other common reactions include diarrhea, stomatitis, paronychia, etc. When adverse reactions occur, the dose needs to be adjusted according to the level of symptoms or the medication must be suspended until the symptoms are relieved.

It is necessary to regularly monitor serum phosphorus concentration and eye health during medication, and seek medical attention promptly if any abnormalities are found.

The medication regimen of tasugatinib succinate

The medication regimen of tasugatinib succinate needs to be determined according to the individual patient's condition, including dose adjustment and long-term management.

Initial treatment and dosage adjustment

In the initial stage of treatment, 140 mg should be taken daily on an empty stomach. If intolerance or side effects occur, the dose can be reduced step by step: from 140mg to 105mg, 70mg or 35mg. Serious adverse reactions require medication to be suspended and treatment to be resumed after symptoms subside.

Long-term monitoring and follow-up

Long-term medication requires regular blood tests and ophthalmological evaluations, focusing on hyperphosphatemia and retinopathy. Patients should record their medication reactions and communicate with their doctors in a timely manner so that the treatment plan can be adjusted.

Use by special groups

Pregnant women, lactating women and children should use it with caution. Dosage adjustments may be required in patients with hepatic impairment. Patients of childbearing potential need to take strict contraceptive measures during and after discontinuation of medication.

Personalized medication regimen is the key to improving efficacy and reducing side effects.

The price of tasugatinib succinate

Tasugatinib succinate is not currently on the market in China, and patients need to obtain the original drug through specific channels.

Market price

The Japanese original drug is 35mg*56 tablets/box, and the price is about US$7,064. The high price may cause a greater financial burden on patients.

Current status of medical insurance and generic drugs

This drug is not included in China’s medical insurance, and there are currently no generic drugs on the market. If it is approved for marketing in China in the future, prices and medical insurance coverage may change.

Drug cost management

Patients can reduce medication costs by consulting doctors or participating in clinical trials. At the same time, attention should be paid to the storage conditions of drugs to avoid waste.

Economic factors may affect treatment choices, and patients need to weigh the efficacy and cost.